parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in cdc	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	2 pathways; mostly other	0.30

No case: the score is under the bar. Receipt 15408

GPR183 in microglia, braak-0.25 (p 0.514) → +0.31 (p 0.414)receipt 15415
GPR183 in dopamine neurons, braak+0.44 (p 0.238) → -0.39 (p 0.299)receipt 15416

receipt 15416: GPR183 in dopamine neurons, braak

power: full sample -0.01 (p 0.969, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.09 (p 0.735, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.17 (p 0.498, n 18). could be the mix.
skeptic: leave-one-out range -0.12 to +0.11, sign flips 6; without severely affected donors -0.01 (p 0.969, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GPR183 in dopamine neurons.

case closed: nothing better to follow up.

receipt 15415: GPR183 in microglia, braak

power: full sample +0.08 (p 0.761, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.04 (p 0.861, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: +0.04 (p 0.888, n 18). could be the mix.
skeptic: leave-one-out range -0.05 to +0.19, sign flips 3; without severely affected donors +0.08 (p 0.761, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for GPR183 in microglia.

case closed: nothing better to follow up.

loading the receipts